TUES 26 MAY 2020
High cost of new cancer drugs in US not related to their effectiveness shows international comparison by LSE
The high costs of recently licensed cancer medicines in the United States – as compared with those in Australia, France and the UK - do not translate into improved survival, quality of life, or safety for patients, according to new research from LSE's Department of Health Policy.
The paper, published in the journal Social Science and Medicine shows that in the US, new drugs cost, in their first year of marketing, on average, US$68,255 per each patient’s course of treatment. This makes them between 1.2 and 1.9 times more expensive than in Australia, France and the UK where costs average US$35,499, US$35,114, and US$55,616 respectively.
Click here for the full story